Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Should l Buy SLNO?
Source: Globenewswire
- Lawsuit Background: Soleno Therapeutics, Inc. (NASDAQ: SLNO) faces a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Soleno made materially false statements regarding its DCCR drug's Phase 3 clinical trial, failing to disclose serious safety concerns, which could undermine investor confidence in the company's future prospects.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to revelations of issues in the clinical trial, reflecting heightened market concerns about the company's viability.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for free legal consultations, highlighting the potential financial losses and risks associated with the ongoing litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.830
Low
75.00
Averages
110.50
High
125.00
Current: 52.830
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Notification: Hagens Berman reminds investors of the lead plaintiff deadline for the securities class action against Soleno Therapeutics (NASDAQ: SLNO) on May 5, 2026, urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses to file claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed serious safety risks associated with its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, including significant concerns about fluid retention and potential heart failure in children using the drug.
- Data Integrity Issues: A report highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising concerns about the integrity of the data and the company's misrepresentation of DCCR's commercial viability.
- Stock Price Plunge: Following Soleno's admission on November 4, 2025, of disruptions in DCCR's launch trajectory, the stock plummeted 27% in a single day, reflecting the market's strong reaction to the company's financial disclosures and safety concerns.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26 and November 4, 2025.
- Concealed Safety Risks: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to undisclosed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, resulting in a 27% stock price drop in one day, reflecting severe market skepticism about its commercial prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as the new SEC whistleblower program offers rewards of up to 30% of any successful recovery, furthering the inquiry into Soleno's practices.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies including Whitestone REIT, Soleno Therapeutics, Odyssey Marine Exploration, and Avanos Medical for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Whitestone REIT Transaction: Whitestone REIT is being sold to Ares Management Corporation for $19.00 per share, and Halper Sadeh LLC may seek to increase the consideration to ensure shareholders receive fair compensation.
- Soleno Therapeutics Transaction: Soleno Therapeutics, Inc. is being sold for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to understand their legal rights, potentially requesting additional disclosures to protect shareholder interests.
- Avanos Medical Transaction: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may advocate for higher consideration and other remedies for shareholders.
See More
ClaimsFiler Alerts Investors on Soleno Therapeutics Securities Class Action
- Deadline for Lawsuit: ClaimsFiler reminds investors in Soleno Therapeutics (SLNO) that they must file lead plaintiff applications by May 5, 2026, to participate in a securities class action lawsuit concerning stock purchases made between March 26, 2025, and November 4, 2025.
- Overview of Legal Charges: The lawsuit alleges that Soleno and certain executives failed to disclose material information during the class period, violating federal securities laws, particularly regarding safety concerns related to its only commercial product, DCCR.
- Safety Risk Concerns: Soleno is accused of systematically minimizing and mischaracterizing potential safety risks in DCCR's clinical trials, which poses greater safety risks than disclosed, thereby affecting the drug's commercial viability.
- Potential Consequences: The undisclosed risks could lead to high patient discontinuation rates, reluctance from prescribers, and potential legal and reputational fallout, which may significantly impact the company's future market performance.
See More
Soleno Therapeutics Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns regarding its DCCR drug during clinical trials, leading to investor losses when the true risks were revealed, indicating that the drug's commercial viability was severely underestimated.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success to ensure optimal representation in the class action, avoiding those that merely act as intermediaries without actual litigation experience.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit with a lead plaintiff deadline of May 5, 2026, urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses to submit their claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno failed to disclose critical safety risks associated with its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, including severe side effects like fluid retention and potential heart failure in children.
- Data Integrity Issues: A report by activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising concerns about the drug's commercial viability and integrity.
- Stock Price Plunge: Following the November 4, 2025, announcement of Q3 financial results, which revealed disruptions in DCCR's launch trajectory, Soleno's stock plummeted 27% in a single day, indicating a severe loss of market confidence in the company's prospects.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Notification: Hagens Berman reminds investors of the lead plaintiff deadline for the securities class action against Soleno Therapeutics (NASDAQ: SLNO) on May 5, 2026, urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses to file claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed serious safety risks associated with its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, including significant concerns about fluid retention and potential heart failure in children using the drug.
- Data Integrity Issues: A report highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising concerns about the integrity of the data and the company's misrepresentation of DCCR's commercial viability.
- Stock Price Plunge: Following Soleno's admission on November 4, 2025, of disruptions in DCCR's launch trajectory, the stock plummeted 27% in a single day, reflecting the market's strong reaction to the company's financial disclosures and safety concerns.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26 and November 4, 2025.
- Concealed Safety Risks: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to undisclosed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, resulting in a 27% stock price drop in one day, reflecting severe market skepticism about its commercial prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as the new SEC whistleblower program offers rewards of up to 30% of any successful recovery, furthering the inquiry into Soleno's practices.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies including Whitestone REIT, Soleno Therapeutics, Odyssey Marine Exploration, and Avanos Medical for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Whitestone REIT Transaction: Whitestone REIT is being sold to Ares Management Corporation for $19.00 per share, and Halper Sadeh LLC may seek to increase the consideration to ensure shareholders receive fair compensation.
- Soleno Therapeutics Transaction: Soleno Therapeutics, Inc. is being sold for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to understand their legal rights, potentially requesting additional disclosures to protect shareholder interests.
- Avanos Medical Transaction: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may advocate for higher consideration and other remedies for shareholders.
See More
ClaimsFiler Alerts Investors on Soleno Therapeutics Securities Class Action
- Deadline for Lawsuit: ClaimsFiler reminds investors in Soleno Therapeutics (SLNO) that they must file lead plaintiff applications by May 5, 2026, to participate in a securities class action lawsuit concerning stock purchases made between March 26, 2025, and November 4, 2025.
- Overview of Legal Charges: The lawsuit alleges that Soleno and certain executives failed to disclose material information during the class period, violating federal securities laws, particularly regarding safety concerns related to its only commercial product, DCCR.
- Safety Risk Concerns: Soleno is accused of systematically minimizing and mischaracterizing potential safety risks in DCCR's clinical trials, which poses greater safety risks than disclosed, thereby affecting the drug's commercial viability.
- Potential Consequences: The undisclosed risks could lead to high patient discontinuation rates, reluctance from prescribers, and potential legal and reputational fallout, which may significantly impact the company's future market performance.
See More
Soleno Therapeutics Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns regarding its DCCR drug during clinical trials, leading to investor losses when the true risks were revealed, indicating that the drug's commercial viability was severely underestimated.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success to ensure optimal representation in the class action, avoiding those that merely act as intermediaries without actual litigation experience.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit with a lead plaintiff deadline of May 5, 2026, urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses to submit their claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno failed to disclose critical safety risks associated with its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, including severe side effects like fluid retention and potential heart failure in children.
- Data Integrity Issues: A report by activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising concerns about the drug's commercial viability and integrity.
- Stock Price Plunge: Following the November 4, 2025, announcement of Q3 financial results, which revealed disruptions in DCCR's launch trajectory, Soleno's stock plummeted 27% in a single day, indicating a severe loss of market confidence in the company's prospects.
See More
